Strengths of the study
To date this is the largest case series of paediatric patients
sustaining vcp secondary to vincristine chemotherapy for ALL occurring
within one tertiary referral centre within the UK. From this we were
able to identify patterns such as laterality, onset of symptoms from
commencing chemotherapy and therefore considerations towards management
of future planned vincristine doses. Time for recovery and treatment
interventions were also identified.
All our patients had no underlying medical conditions prior to being
diagnosed with ALL nor where they on any medications known to increase
the toxicity. We could therefore deduce our finding from a comparative
selection of paediatric patients and compare our case series to other
cases reported in the literature and guide clinicians faced with this
clinical situation.